neutrogena skincare , page-38

shnan,

The last time I did exactly as you have with your last post I was suspended from HC for 1 month with the following "public" message from the moderators left on my profile:

"Public: this is complete plagiarism. To take others words and post them as your own is completely unacceptable"

I'm not having a dig, nor have I tou'd you because imo it can be a simple and easy mistake to not to provide the source of your information.

A lot of what's been written in that article provides the answer for why I'm invested most heavily in OBJ and not a company focussed on developing drugs. (with the small exception of PRR)

I think there still remains less than a 2% success rate for new drugs receiving final FDA approval. Drug delivery devices is up around the 25% mark.

On another note, I still don't understand why Pfizer dumped that Rigel deal. One of the most crazy decisions I've seen by big pharma for a long while...
__________

Novel drug delivery critical to pharma's future - December 14, 2010

"It is 'a must' for pharmaceutical firms to establish 'wise' partnerships with emerging delivery developers, according to Sintuu, as these will help maintain a competitive edge through innovative start-ups along the value chain.

Referring to the ever growing number of drug patent expirations set to hit big pharma firms in the next few years - Pfizer's Lipitor (atorvastatin calcium) being one example - Sintuu said that between 2012 and 2014, over $140bn in sales revenue will disappear as a direct result.

With this in mind, she argues "these corporations are scrambling for the next blockbuster drug when they should really start to consider developing more effective delivery systems."

Sintuu highlighted that innovative delivery systems may provide benefits in a drug's efficacy, ease of use or cost. Also, the simple novelty of a delivery system can "really move a product to the top of a shopper's list." source ;)